Ancora Advisors LLC Has $123,000 Stock Holdings in GSK PLC Sponsored ADR $GSK

Key Points

• Ancora Advisors LLC significantly reduced its stake in GSK PLC by selling 9,805 shares, resulting in a 75.6% decrease in holdings.
• Several institutional investors, including Dodge & Cox and Primecap Management Co., increased their stakes in GSK during the first quarter.
• GSK's latest earnings report revealed an EPS of $1.23, exceeding analyst expectations, with revenue reported at $10.64 billion, indicating a year-over-year growth of 1.3%.

Ancora Advisors LLC decreased its stake in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 75.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,166 shares of the pharmaceutical company's stock after selling 9,805 shares during the period. Ancora Advisors LLC's holdings in GSK were worth $123,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. HHM Wealth Advisors LLC increased its stake in GSK by 222.2% during the 1st quarter. HHM Wealth Advisors LLC now owns 667 shares of the pharmaceutical company's stock valued at $26,000 after buying an additional 460 shares during the period. Costello Asset Management INC acquired a new position in shares of GSK in the 1st quarter worth approximately $31,000. Richardson Financial Services Inc. grew its stake in shares of GSK by 127.9% in the 1st quarter. Richardson Financial Services Inc. now owns 841 shares of the pharmaceutical company's stock worth $33,000 after purchasing an additional 472 shares during the last quarter. Olde Wealth Management LLC acquired a new position in shares of GSK in the 1st quarter worth approximately $36,000. Finally, Cary Street Partners Investment Advisory LLC grew its stake in shares of GSK by 525.9% in the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 1,014 shares of the pharmaceutical company's stock worth $39,000 after purchasing an additional 852 shares during the last quarter. Institutional investors and hedge funds own 15.74% of the company's stock.

GSK Trading Down 1.6%

Shares of GSK traded down $0.67 during midday trading on Friday, hitting $40.81. The stock had a trading volume of 4,741,956 shares, compared to its average volume of 3,553,270. GSK PLC Sponsored ADR has a fifty-two week low of $31.72 and a fifty-two week high of $43.62. The business has a 50-day simple moving average of $38.74 and a two-hundred day simple moving average of $38.46. The firm has a market cap of $83.12 billion, a P/E ratio of 18.89, a price-to-earnings-growth ratio of 2.07 and a beta of 0.53. The company has a current ratio of 0.87, a quick ratio of 0.57 and a debt-to-equity ratio of 1.07.

GSK (NYSE:GSK - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 EPS for the quarter, topping the consensus estimate of $1.12 by $0.11. The business had revenue of $10.64 billion during the quarter, compared to analysts' expectations of $7.92 billion. GSK had a net margin of 10.81% and a return on equity of 49.22%. The firm's quarterly revenue was up 1.3% compared to the same quarter last year. During the same period last year, the company posted $0.43 earnings per share. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. As a group, equities analysts forecast that GSK PLC Sponsored ADR will post 4.14 EPS for the current year.

GSK Cuts Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 9th. Shareholders of record on Friday, August 15th will be paid a $0.4206 dividend. The ex-dividend date is Friday, August 15th. This represents a $1.68 dividend on an annualized basis and a yield of 4.1%. GSK's payout ratio is 77.78%.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on GSK shares. Berenberg Bank reaffirmed a "hold" rating on shares of GSK in a research note on Tuesday, June 3rd. Wall Street Zen raised shares of GSK from a "buy" rating to a "strong-buy" rating in a research note on Friday, September 5th. Six research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Reduce" and a consensus target price of $37.38.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.